Pyroptosis marker, including GSDME‐N, was also detected in the HMB and combination treatment groups, indicating that HMB‐induced GSDME‐dependent pyroptosis enhanced tumor immunogenicity (Figure 10J). The gene discussed is GSDME; the disease is neoplasm.